Participants who were given 150,000 endothelial cells experienced an average gain of 11 letters in Best Corrected Visual ...

The trial is structured as a non-randomised, open-label study in patients with relapsed, resistant or metastatic HPV-related ...

The topline results found that the TenNor rifasutenizol trial showed better safety and tolerability than the current standard ...

New data from Barinthus Bio's HBV003 trial has demonstrated durable HBsAG loss in participants with chronic hepatitis B.

At AHA 2024, the safety of GLP-1R agonists in heart failure and chronic kidney disease (CKD) patients was discussed.

Lilly has reported comprehensive outcomes from the Phase III trial of tirzepatide for individuals with heart failure with ...

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) ...

The failure of the Eyenovia CHAPERONE study has seen the company’s stock value drop drastically as it weighs up options and ...

The discussion at AHA emphasised that the FLOW trial established that semaglutide prevents major kidney outcomes and major ...

The ASI drug class potentially fills an unmet need in the CKD space. Credit: crystal light via Shutterstock. On 15 November ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide for treating pre-diabetic and obese ...